Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Core Assembly Inhibitor is a small molecule drug candidate being developed by Chromis Therapeutics for the treatment of chronic Hepatitis B Virus (HBV) infection. It belongs to a class of agents known as capsid assembly modulators (CAMs). The drug specifically targets the HBV core protein (HBcAg), interfering with the critical step of viral capsid assembly. By disrupting the formation of the nucleocapsid, the inhibitor prevents the encapsidation of the viral pregenomic RNA (pgRNA) and the subsequent reverse transcription into viral DNA. This mechanism effectively blocks the production of new virions and reduces the viral load. The program is currently in the preclinical stage of development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Core Assembly Inhibitor.